stockportfolio.pro
Stocks / BCRX vs LMAT
BCRX vs LMAT
BioCryst Pharmaceuticals, Inc. and LeMaitre Vascular, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| BioCryst Pharmaceuticals, Inc. (BCRX) | LeMaitre Vascular, Inc. (LMAT) | |
|---|---|---|
| Market cap | $2.1B | $2.1B |
| Revenue (latest FY) | $874.84M | $249.60M |
| Net income (latest FY) | $263.86M | $57.73M |
| Revenue growth (5y CAGR) | 117.9% | 14.0% |
| Net margin | 30.2% | 23.1% |
| Return on equity | -221.4% | 14.7% |
| P/E ratio | — | 34.1 |
| Dividend yield | — | 1.0% |
| Profitable years (of last 10) | 1 | 10 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BCRX — free Open LMAT — freeFrequently asked questions
Which is bigger, BCRX or LMAT?
BioCryst Pharmaceuticals, Inc. is larger by market capitalization — $2.1B versus $2.1B.
Which grows faster, BCRX or LMAT?
Over the last five fiscal years, BioCryst Pharmaceuticals, Inc. grew revenue faster — 117.9%/yr versus 14.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.